Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001989 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin
A Phase 2 study of HIV Infections, sponsored by Genelabs Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Study locations
NCT00001989 is a Phase 2 study of HIV Infections that has completed, run by Genelabs Technologies. The trial reports 8 study locations across 4 states.
The verdict
NCT00001989, a Phase 2 study of HIV Infections, has completed, sponsored by Genelabs Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8
- Study locations
Study Summary
This study involves GLQ223 administration to patients who have not previously been exposed to it, but who have received at least 9 months of zidovudine therapy. Efficacy evaluations will include survival, opportunistic infections, T4 cell count, and assessments of viral load.
Conditions Studied
Interventions
- DRUG Zidovudine
- DRUG Trichosanthin
Study Locations (8)
California
- ViRx Inc - San Francisco
- Dr Larry A Waites - San Francisco
- Saint Francis Mem Hosp - San Francisco
- UCSF - San Francisco Gen Hosp - San Francisco
Florida
- Miami Veterans Administration Med Ctr - Miami
- Infectious Disease Research Institute Inc - Tampa
Illinois
- Northwestern Univ - Chicago
New York
- Saint Vincent's Hosp and Med Ctr - New York
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001989
The ClinicalTrials.gov registry entry for NCT00001989 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Genelabs Technologies, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Zidovudine is the first listed.
NCT00001989 reports 8 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00001989 about?
NCT00001989 is a clinical study titled "A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin". This study involves GLQ223 administration to patients who have not previously been exposed to it, but who have received at least 9 months of zidovudine therapy. Efficacy evaluations will include survival, opportunistic infections, T4 cell count, and assessments of viral load.
What is the current status of trial NCT00001989?
This trial is currently completed. It is a Phase 2 study.
What conditions does trial NCT00001989 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00001989?
The interventions under investigation include: Zidovudine (DRUG), Trichosanthin (DRUG).
Who is sponsoring clinical trial NCT00001989?
This trial is sponsored by Genelabs Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001989 being conducted?
This trial has 8 study locations across California, Florida, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.